Techcyte has successfully secured $15 million in funding to enhance its AI-driven diagnostics platform, Fusion, which integrates anatomic and clinical pathology into a unified digital workflow.
Led by Van Tuyl Companies and supported by notable partners like Mayo Clinic and Zoetis, this funding round marks a significant step for Techcyte as it aims for profitability and expansion into medical, veterinary, and environmental health sectors. The need for advanced AI solutions is underscored by the increasing demand for diagnostic services and a global shortage of laboratory personnel.
Techcyte's Fusion platform leverages deep learning algorithms to improve the accuracy of identifying parasitic cells, bacteria, and cancer cells, facilitating remote case reviews through digitized samples. This innovative approach addresses the challenges labs face in managing higher workloads with limited resources, as noted by CEO Ben Cahoon.
A key advantage of this funding is access to Mayo Clinic’s extensive Safe Harbour dataset, which contains over 17 million de-identified pathology reports. This resource is expected to enhance the development of diagnostic tests and refine existing algorithms. Techcyte’s profitable veterinary segment positions it favorably, with expectations for its human and environmental divisions to achieve similar success by 2027.
Techcyte’s strategy emphasizes openness and interoperability, allowing its Fusion platform to integrate with various digital slide scanners and lab systems. Recent collaborations, such as with Modella AI, showcase the company's commitment to remaining at the forefront of AI advancements in healthcare. With this new funding, Techcyte is poised to become a foundational software provider in the evolving landscape of diagnostic laboratories.